Vitamin D (VD) deficiency is a growing problem, affecting a significant portion of the population in many countries. VD deficiency may be related to several diseases, including Alzheimer's disease (AD). This study aimed to review the relationship between VD deficiency and AD. We describe the proteins involved in AD pathogenesis and how those proteins can be influenced by VD deficiency. We also investigated a relationship between AD death rate and solar radiation and we found an increased AD death rate in countries with low sunlight. It was also observed that amyloid precursor protein, ryanodine receptor, mammalian target of rapamycin complex 1, and receptor for advanced glycation end products are associated with a worse prognosis in AD. While the Klotho protein, phosphatase and tensin homologue, and VD receptor are associated with a better prognosis in the disease. The literature suggests that decline in VD concentrations may be involved in the establishment and progression of AD. According to sunlight data, we can conclude that countries with low average sunlight have high AD death rate.
Get full access to this article
View all access options for this article.
References
1.
BuellJS, Dawson-HughesB: Vitamin D and neurocognitive dysfunction: Preventing “D”ecline?. Mol Aspects Med, 2008; 29:415–422.
2.
GarcionE, NatafS, BerodA, DarcyF, BrachetP: 1,25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Mol Brain Res, 1997; 45:255–267.
3.
JainSK, MicinskiD: Vitamin D upregulates glutamate cysteine ligase and glutathione reductase, and GSH formation, and decreases ROS and MCP-1 and IL-8 secretion in high-glucose exposed U937 monocytes. Biochem Biophys Res Commun, 2013; 437:7–11.
4.
LongoniA, KollingJ, SiebertC, et al.: 1,25-Dihydroxyvitamin D3 prevents deleterious effects of homocysteine on mitochondrial function and redox status in heart slices. Nutr Res, 2017; 38:52–63.
5.
SerrettiA, OlgiatiP, De RonchiD: Genetics of Alzheimer's disease. A rapidly evolving field. J Alzheimers Dis, 2007; 12:73–92.
6.
ThacherTD, ClarkeBL: Vitamin D insufficiency. Mayo Clin Proc, 2011; 86:50–60.
7.
TanikN, BalbaloğluÖ, UcarM, et al.: Does vitamin D deficiency trigger carpal tunnel syndrome?. J Back Musculoskelet Rehabil, 2016; 29:835–839.
8.
NissouM-F, BrocardJ, El AtifiM, et al.: The transcriptomic response of mixed neuron-glial cell cultures to 1,25-dihydroxyvitamin d3 includes genes limiting the progression of neurodegenerative diseases. J Alzheimers Dis, 2013; 35:553–564.
9.
ValenzuelaMJ, SachdevP: Magnetic resonance spectroscopy in AD. Neurology, 2001; 56:592–598.
10.
SakuraiT, OgamaN, TobaK: Lower vitamin D is associated with white matter hyperintensity in elderly women with Alzheimer's disease and amnestic mild cognitive impairment. J Am Geriatr Soc, 2014; 62:1993–1994.
11.
SteinMS, SchererSC, LaddKS, HarrisonLC: A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease. J Alzheimers Dis, 2011; 26:477–484.
12.
PrzybelskiR, AgrawalS, KruegerD, EngelkeJA, WalbrunF, BinkleyN: Rapid correction of low vitamin D status in nursing home residents. Osteoporos Int, 2008; 19:1621–1628.
13.
PepperK, JuddS, NanesM, TangprichaV: Evaluation of vitamin D repletion regimens to correct vitamin D status in adults. Endocr Pract, 2009; 15:95–103.
14.
LittlejohnsTJ, HenleyWE, LangIA, et al.: Vitamin D and the risk of dementia and Alzheimer disease. Neurology, 2014; 83:920–928.
15.
WeglerC, WikvallK, NorlinM: Effects of osteoporosis-inducing drugs on vitamin D-related gene transcription and mineralization in MG-63 and Saos-2 cells. Basic Clin Pharmacol Toxicol, 2016; 119:436–442.
16.
BoothDR, DingN, ParnellGP, et al.: Cistromic and genetic evidence that the vitamin D receptor mediates susceptibility to latitude-dependent autoimmune diseases. Genes Immun, 2016; 17:213–219.
17.
BanerjeeA, KhemkaVK, GangulyA, RoyD, GangulyU, ChakrabartiS: Vitamin D and Alzheimer's disease: Neurocognition to therapeutics. Int J Alzheimers Dis, 2015; 2015:192747.
18.
LemireP, BrangierA, BeaudenonM, DuvalGT, AnnweilerC: Cognitive changes under memantine according to vitamin D status in Alzheimer patients: An exposed/unexposed cohort pilot study. J Steroid Biochem Mol Biol, 2018; 175:151–156.
19.
MokryLE, RossS, MorrisJA, ManousakiD, ForgettaV, RichardsJB: Genetically decreased vitamin D and risk of Alzheimer disease. Neurology, 2016; 87:2567–2574.
20.
DursunE, AlaylıoğluM, BilgiçB, et al.: Vitamin D deficiency might pose a greater risk for ApoEɛ4 non-carrier Alzheimer's disease patients. Neurol Sci, 2016; 37:1633–1643.
21.
ChavesM, ToralA, BisonniA, et al.: Treatment with vitamin D and slowing of progression to severe stage of Alzheimer's disease. Vertex, 2014; 25:85–91.
22.
ŁaczmańskiŁ, JakubikM, Bednarek-TupikowskaG, RymaszewskaJ, SłokaN, LwowF: Vitamin D receptor gene polymorphisms in Alzheimer's disease patients. Exp Gerontol, 2015; 69:142–147.
23.
Castro LCG de: The vitamin D endocrine system. Arq Bras Endocrinol Metabol, 2011; 55:566–575.
24.
WebbAR, AseemS, KiftRC, RhodesLE, FarrarMD: Target the message: A qualitative study exploring knowledge and cultural attitudes to sunlight and vitamin D in Greater Manchester, U.K. Br J Dermatol, 2016; 175:1401–1403.
25.
KrzywanskiJ, MikulskiT, KrysztofiakH, MlynczakM, GaczynskaE, ZiembaA: Seasonal Vitamin D status in polish elite athletes in relation to sun exposure and oral supplementation. PLoS One, 2016; 11:e0164395.
26.
LivingstoneKM, Celis-MoralesC, HoellerU, et al.: Weekday sunlight exposure, but not vitamin D intake, influences the association between vitamin D receptor genotype and circulating concentration 25-hydroxyvitamin D in a pan-European population: The Food4Me study. Mol Nutr Food Res, 2017; 61:1600476.
27.
RazzaqueMS: Sunlight exposure: Do health benefits outweigh harm?. J Steroid Biochem Mol Biol, 2018; 175:44–48.
28.
O'BrienRJ, WongPC: Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci, 2011; 34:185–204.
29.
MullerUC, ZhengH: Physiological functions of APP family proteins. Cold Spring Harb Perspect Med, 2012; 2:a006288–a006288.
30.
KeeneyJT, ButterfieldDA: Vitamin D deficiency and Alzheimer disease: Common links. Neurobiol Dis, 2015; 84:84–98.
31.
AbrahamCR, ChenC, CunyGD, GlicksmanMA, ZeldichE: Small-molecule Klotho enhancers as novel treatment of neurodegeneration. Future Med Chem, 2012; 4:1671–1679.
JackCR, AlbertMS, KnopmanDS, et al.: Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement, 2011; 7:257–262.
34.
OjopiEPB, BertonciniAB, Dias NetoE: Apolipoproteína E e a doença de Alzheimer. Arch Clin Psychiatry (São Paulo), 2004; 31:26–33.
35.
CaselliRJ, ReimanEM: Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention. J Alzheimers Dis, 2013; 33Suppl 1:S405–S416.
36.
LannerJT, GeorgiouDK, JoshiAD, HamiltonSL: Ryanodine receptors: Structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol, 2010; 2:a003996–a003996.
37.
Franzini-ArmstrongC, ProtasiF: Ryanodine receptors of striated muscles: A complex channel capable of multiple interactions. Physiol Rev, 1997; 77:699–729.
38.
LinAMY, ChenKB, ChaoPL: Antioxidative effect of vitamin D3 on zinc-induced oxidative stress in CNS. Ann N Y Acad Sci, 2005; 1053:319–329.
39.
BaoB-Y, TingH-J, HsuJ-W, LeeY-F: Protective role of 1α, 25-dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells. Int J Cancer, 2008; 122:2699–2706.
40.
BhattacharyyaA, ChattopadhyayR, MitraS, CroweSE: Oxidative stress: An essential factor in the pathogenesis of gastrointestinal mucosal diseases. Physiol Rev, 2014; 94:329–354.
41.
MokhtariZ, HekmatdoostA, NourianM: Antioxidant efficacy of vitamin D. J Parathyr Dis, 2016; 5:11–16.
42.
BerridgeMJ: Vitamin D cell signalling in health and disease. Biochem Biophys Res Commun, 2015; 460:53–71.
43.
SembaRD, MoghekarAR, HuJ, et al.: Klotho in the cerebrospinal fluid of adults with and without Alzheimer's disease. Neurosci Lett, 2014; 558:37–40.
44.
Di BonaD, AccardiG, VirrusoC, CandoreG, CarusoC: Association of Klotho polymorphisms with healthy aging: A systematic review and meta-analysis. Rejuvenation Res, 2014; 17:212–216.
45.
MoeSM: Klotho: A master regulator of cardiovascular disease?. Circulation, 2012; 125:2181–2183.
46.
DubalDB, YokoyamaJS, ZhuL, et al.: Life extension factor Klotho enhances cognition. Cell Rep, 2014; 7:1065–1076.
47.
WirrigEE, GomezMV, HintonRB, YutzeyKE: COX2 inhibition reduces aortic valve calcification in vivo significance. Arterioscler Thromb Vasc Biol, 2015; 35:938–947.
HansenM, KapahiP: 14–TOR signaling and aging. Enzym, 2010; 28:279–299.
50.
YinY, ShenWH: PTEN: A new guardian of the genome. Oncogene, 2008; 27:5443–5453.
51.
KreisP, LeondaritisG, LieberamI, EickholtBJ: Subcellular targeting and dynamic regulation of PTEN: Implications for neuronal cells and neurological disorders. Front Mol Neurosci, 2014; 7:23.
52.
PanL, MatloobAF, DuJ, et al.: Vitamin D stimulates apoptosis in gastric cancer cells in synergy with trichostatin A/sodium butyrate-induced and 5-aza-2′-deoxycytidine-induced PTEN upregulation. FEBS J, 2010; 277:989–999.
53.
ZhangX, LiF, BullojA, et al.: Tumor-suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules. FASEB J, 2006; 20:1272–1274.
54.
Yan SDu, BierhausA, NawrothPP, SternDM: RAGE and Alzheimer's disease: A progression factor for amyloid-beta-induced cellular perturbation?. J Alzheimers Dis, 2009; 16:833–843.
55.
ChavakisT, BierhausA, NawrothP: RAGE (receptor for advanced glycation end products): A central player in the inflammatory response. Microbes Infect, 2004; 6:1219–1225.
56.
LubitzI, RicnyJ, Atrakchi-BaranesD, et al.: High dietary advanced glycation end products are associated with poorer spatial learning and accelerated A$β$ deposition in an Alzheimer mouse model. Aging Cell, 2016; 15:309–316.
57.
CaiZ, LiuN, WangC, et al.: Role of RAGE in Alzheimer's disease. Cell Mol Neurobiol, 2016; 36:483–495.
58.
TangZ, IojaE, BereczkiE, et al.: mTor mediates tau localization and secretion: Implication for Alzheimer's disease. Biochim Biophys Acta Mol Cell Res, 2015; 1853:1646–1657.
59.
ZhuS, ShalaA, BezginovA, SljokaA, AudetteG, WilsonDJ: Hyperphosphorylation of intrinsically disordered Tau protein induces an amyloidogenic shift in its conformational ensemble. PLoS One, 2015; 10:e0120416.
60.
BraakH, BraakE, StrothjohannM: Abnormally phosphorylated tau protein related to the formation of neurofibrillary tangles and neuropil threads in the cerebral cortex of sheep and goat. Neurosci Lett, 1994; 171:1–4.
61.
HongY, AnZ: Hesperidin attenuates learning and memory deficits in APP/PS1 mice through activation of Akt/Nrf2 signaling and inhibition of RAGE/NF-κB signaling. Arch Pharm Res, 2015. DOI:org/10.1007/s12272-015-0662-z.
62.
DaborgJ, von OtterM, SjölanderA, et al.: Association of the RAGE G82S polymorphism with Alzheimer's disease. J Neural Transm, 2010; 117:861–867.
63.
GuoY-X, HeL-Y, ZhangM, WangF, LiuF, PengW-X: 1,25-Dihydroxyvitamin D3 regulates expression of LRP1 and RAGE in vitro and in vivo, enhancing Aβ1–40 brain-to-blood efflux and peripheral uptake transport. Neuroscience, 2016; 322:28–38.
64.
LeeT-W, KaoY-H, LeeT-I, ChangC-J, LienG-S, ChenY-J: Calcitriol modulates receptor for advanced glycation end products (RAGE) in diabetic hearts. Int J Cardiol, 2014; 173:236–241.
65.
Zitman-GalT, GolanE, GreenJ, BernheimJ, BenchetritS: Vitamin D receptor activation in a diabetic-like environment: Potential role in the activity of the endothelial pro-inflammatory and thioredoxin pathways. J Steroid Biochem Mol Biol, 2012; 132:1–7.
PikeJW, MeyerMB: The vitamin D receptor: New paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). Endocrinol Metab Clin North Am, 2010; 39:255–269.
68.
BouillonR, EelenG, VerlindenL, MathieuC, CarmelietG, VerstuyfA: Vitamin D and cancer. J Steroid Biochem Mol Biol, 2006; 102:156–162.
69.
KatoS: The function of vitamin D receptor in vitamin D action. J Biochem, 2000; 127:717–722.
70.
WangL, HaraK, Van BaarenJM, et al.: Vitamin D receptor and Alzheimer's disease: A genetic and functional study. Neurobiol Aging, 2012; 33:1844.e1–1844.e9.
71.
DursunE, Gezen-AkD, YilmazerS: A novel perspective for Alzheimer's disease: Vitamin D receptor suppression by amyloid-β and preventing the amyloid-β induced alterations by vitamin D in cortical neurons. J Alzheimers Dis, 2011; 23:207–219.
72.
KingL, DearK, HarrisonSL, et al.: Investigating the patterns and determinants of seasonal variation in vitamin D status in Australian adults: The Seasonal D Cohort Study. BMC Public Health, 2016; 16:892.
73.
MendezMF: Early-onset Alzheimer's disease: Nonamnestic subtypes and type 2 AD. Arch Med Res, 2012; 43:677–685.
74.
QuerfurthHW, LaFerlaFM: Alzheimer's disease. N Engl J Med, 2010; 362:329–344.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
